GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Appili Therapeutics Inc (OTCPK:APLIF) » Definitions » Inventories, Raw Materials & Components

APLIF (Appili Therapeutics) Inventories, Raw Materials & Components : $0.00 Mil (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Appili Therapeutics Inventories, Raw Materials & Components?

Appili Therapeutics's inventories, raw materials & components for the quarter that ended in Sep. 2024 was $0.00 Mil.


Appili Therapeutics Inventories, Raw Materials & Components Historical Data

The historical data trend for Appili Therapeutics's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Appili Therapeutics Inventories, Raw Materials & Components Chart

Appili Therapeutics Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Inventories, Raw Materials & Components
Get a 7-Day Free Trial 0.03 - - - -

Appili Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Appili Therapeutics Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.


Appili Therapeutics Business Description

Industry
Traded in Other Exchanges
Address
1344 Summer Street, Suite 21, Halifax, NS, CAN, B3H 0A8
Appili Therapeutics Inc is a biopharmaceutical company. The company is engaged in novel antibiotic and anti-infective therapies to help patients suffering from serious infections. Its anti-infective portfolio currently includes programs namely ATI-1701, ATI-1801.